Clinical Trial Update: High-activity Natural Killer Immunotherapy for Small Metastases of Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating a high-activity natural killer immunotherapy for small metastases in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• High-activity Natural Killer immunotherapy

Snippet

Sponsor: Fuda Cancer Hospital, Guangzhou | Conditions: Non-small Cell Lung Cancer Metastatic | Phase 1, Phase 2 | Status: COMPLETED